Introduction {#section1-1756283X17750355}
============

The two most common forms of inflammatory bowel disease (IBD) are Crohn's disease (CD) and ulcerative colitis (UC). Both are chronic, immune-mediated inflammatory disorders of the gastrointestinal tract, characterized by abdominal pain, rectal bleeding, diarrhoea and fatigue.^[@bibr1-1756283X17750355][@bibr2-1756283X17750355]--[@bibr3-1756283X17750355]^ In 2012, CD was reported to affect between 319 (North America) and 322 (Europe) people per 100,000, and UC between 249 (North America) and 505 (Europe) people per 100,000, with the prevalence of both diseases reported to be increasing in both regions.^[@bibr4-1756283X17750355]^

Agents currently approved for the treatment of IBD include 5-aminosalicylic acid, corticosteroids, methotrexate (MTX), the thiopurines azathioprine and mercaptopurine and biologic therapies targeting tumour necrosis factor (TNF)-alpha and integrins.^[@bibr5-1756283X17750355][@bibr6-1756283X17750355]--[@bibr7-1756283X17750355]^ Both the American College of Gastroenterology and European Crohn's and Colitis Organisation guidelines advise that treatment should be tailored to the individual, considering disease severity and location, with biologic therapies considered for those with moderate to severe disease who do not respond to, or are intolerant of, conventional therapy.^[@bibr5-1756283X17750355][@bibr6-1756283X17750355][@bibr7-1756283X17750355][@bibr8-1756283X17750355]--[@bibr9-1756283X17750355]^

Although biologic therapies represent a major advance in the treatment of IBD, and a high proportion of patients with moderate or severe disease respond well to biologics, at least 30% of patients fail to meet primary endpoints in clinical trials,^[@bibr10-1756283X17750355],[@bibr11-1756283X17750355]^ and a proportion of patients lose response over time.^[@bibr12-1756283X17750355]^ Immunogenicity is recognized as a leading contributor to the loss of response to biologic therapies; as biologic agents are large, complex proteins, they trigger the formation of anti-drug antibodies (ADAbs) specific to the agent administered.^[@bibr13-1756283X17750355]^ Therefore, it is recommended that patients who develop ADAbs to a biologic therapy, with a consequent loss of response, should switch to a different agent with either the same or a different mechanism of action.^[@bibr14-1756283X17750355][@bibr15-1756283X17750355]--[@bibr16-1756283X17750355]^

Studies of the immunogenicity of biologics have reported variability in the rate of formation of ADAbs, and in the time post-exposure that ADAbs develop, possibly due to differing immunogenicity assay methodologies.^[@bibr13-1756283X17750355]^ A number of different techniques with varying specificity, sensitivity and cost are currently available to measure ADAbs. Assay techniques include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and electrochemi-luminescence (ECL), with some methods optionally incorporating an acid-dissociation step to improve sensitivity and increase the chances of detecting ADAbs even in the presence of high levels of antigen.^[@bibr17-1756283X17750355][@bibr18-1756283X17750355][@bibr19-1756283X17750355]--[@bibr20-1756283X17750355]^

Aim {#section2-1756283X17750355}
===

The objective of the current analysis was to evaluate and contextualize the immunogenicity of approved biologic therapies used to treat IBD in order to understand the clinical implications of the rate, timeline and impact of the development of an immunogenic response to biologics.

Methods {#section3-1756283X17750355}
=======

The methodological approach was described in a protocol and followed the recommendations and standards required by the UK National Institute for Health and Care Excellence (NICE) and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.

Literature search {#section4-1756283X17750355}
-----------------

A comprehensive search strategy was developed, and online searches were conducted for relevant articles published in the period January 2009 to August 2015.

A number of electronic sources were searched: Medline^®^ and Embase^®^ via the Ovid interface; Cochrane Central Register of Trials (CENTRAL); Cochrane Database of Systematic Review (CDSR); NHS Economic Evaluation Database (NHS EED); Health Technology Assessment (HTA) Database; and Database of Abstracts of Reviews of Effects (DARE) via the Cochrane Library. In addition to the online search, key congresses, published systematic literature reviews (capturing suitable studies published prior to 2009) and the references in articles relevant to the topic of interest were hand-searched. Details of the search strategies are included as [Supplementary Tables 1](http://journals.sagepub.com/doi/suppl/10.1177/1756283X17750355) and [2](http://journals.sagepub.com/doi/suppl/10.1177/1756283X17750355).

Study eligibility and screening {#section5-1756283X17750355}
-------------------------------

Randomized controlled trials (RCTs), non-RCTs and observational studies of patients with CD or UC were eligible. Case reports, case series, literature reviews, letters, commentaries and editorials were excluded. Studies were included if they reported data for the biologics adalimumab (ADM), certolizumab pegol (CZP), golimumab (GLM), infliximab (IFX), ustekinumab (UST) and vedolizumab (VDM), administered to patients with CD or UC either as monotherapy or in combination with conventional therapy.

Abstracts identified from the online search were screened for eligibility by a reviewer. A second, independent reviewer checked 10% of screened abstracts. Articles considered eligible were obtained and subjected to full-text review; any ineligible studies were excluded, with the rationale for exclusion documented. A second independent reviewer screened 20% of excluded publications and all eligible publications; any discrepancies between reviewers were resolved by consensus.

Data extraction and quality assessment {#section6-1756283X17750355}
--------------------------------------

Relevant information was defined at the start of the study, and a data extraction table ( [Supplementary Table 3](http://journals.sagepub.com/doi/suppl/10.1177/1756283X17750355)) was developed to collect information obtained on full review of the selected articles. Selected articles were assessed for quality in accordance with the recommended methodology for systematic literature reviews.^[@bibr21-1756283X17750355]^ One reviewer screened all citations and full-text papers, which were then double-checked by an independent reviewer. Likewise, data extraction was conducted by a single reviewer, and subsequently validated by an independent reviewer. For RCTs, the quality of selected articles was assessed according to the NICE single technology appraisal manufacturer's template^[@bibr22-1756283X17750355]^ and the Jadad scoring system.^[@bibr23-1756283X17750355]^ The quality of selected non-RCTs and observational studies was assessed using the Downs and Black instrument.^[@bibr24-1756283X17750355]^ Abstracts from conference proceedings were assessed using a modified version of the Downs and Black instrument. Studies scoring poorly on any of the quality assessments were excluded from the main analyses.

Results {#section7-1756283X17750355}
=======

Literature search {#section8-1756283X17750355}
-----------------

A total of 22,334 abstracts were identified and screened for eligibility; 938 articles were retrieved for full-text review, and 114 studies reported in 122 publications were finally assessed ([Figure 1](#fig1-1756283X17750355){ref-type="fig"} and [Supplementary Table 4](http://journals.sagepub.com/doi/suppl/10.1177/1756283X17750355)).

![PRISMA flow diagram of screening and selection process.\
*n*, number; SLR, systematic literature review.](10.1177_1756283X17750355-fig1){#fig1-1756283X17750355}

Based on the full-text review of selected articles, five studies were excluded due to low-quality assessment scores. Details of these studies, and the reasons for their exclusion, are provided in [Supplementary Table 5](http://journals.sagepub.com/doi/suppl/10.1177/1756283X17750355).

Over 90% of studies included in the review involved administration of ADM or IFX. Only a few studies were available for other agents; four, two, one and four studies were identified concerning CZP, GLM, UST and VDM treatment in IBD, respectively.

Rates of immunogenicity in patients receiving treatment with biologics {#section9-1756283X17750355}
----------------------------------------------------------------------

Rates of ADAb formation were extremely variable ([Table 1](#table1-1756283X17750355){ref-type="table"}). A brief summary of factors affecting the formation and detection of ADAbs is provided in [Supplementary Table 6](http://journals.sagepub.com/doi/suppl/10.1177/1756283X17750355). A total of 12 RCTs and 62 non-RCTs or observational studies of IFX were reviewed, and rates of over 60% were observed in six of these studies. The highest rates of ADAb formation were associated with IFX in patients with CD or UC ([Table 1](#table1-1756283X17750355){ref-type="table"}). The highest rate for any other agent was 38% for ADM in one retrospective cohort study ([Table 1](#table1-1756283X17750355){ref-type="table"}).

###### 

Range of rates (%) of ADAbs formation to biologics in patients with IBD^[a](#table-fn1-1756283X17750355){ref-type="table-fn"},[b](#table-fn2-1756283X17750355){ref-type="table-fn"}^.

![](10.1177_1756283X17750355-table1)

  Biologic agent                                                      All studies (*n*)   CD (*n*)         UC (*n*)        CD or UC (*n*)
  ------------------------------------------------------------------- ------------------- ---------------- --------------- ----------------
  Infliximab^[c](#table-fn3-1756283X17750355){ref-type="table-fn"}^   0.0--65.3 (73)      2.9--60.8 (22)   6.1--41.0 (8)   0.0--65.3 (43)
  Adalimumab                                                          0.3--38.0 (22)      0.3--35.0 (11)   2.9--5.3 (3)    14.0--38.0 (8)
  Certolizumab pegol                                                  3.3--25.3 (4)       3.3--25.3 (4)    --              --
  Vedolizumab                                                         1.0--4.1 (4)        1.0--4.1 (2)     3.7 (1)         4.0 (1)
  Golimumab                                                           0.4--2.9 (2)        --               0.4--2.9 (2)    --
  Ustekinumab                                                         0.7 (1)             0.7 (1)          --              --

Only studies reporting rates of ADAbs were included (eight studies did not report specific proportions of patients developing ADAbs).

Immunogenicity analyses are product- and assay-specific.

One selected study was excluded from analysis as this had a small sample size (*n* = 28) and a high rate of immunogenicity (79%).

--, no publications available; ADAbs, anti-drug antibodies; CD, Crohn's disease; *n*, number of studies; UC, ulcerative colitis.

Rates of immunogenicity in patients receiving treatment with infliximab {#section10-1756283X17750355}
-----------------------------------------------------------------------

In total, 82 publications were identified, representing 78 studies on the immunogenicity of IFX; the majority of these (87.2%) were observational studies. Of the 78 studies reviewed, 74 reported the percentage of patients developing ADAbs to IFX. One of these studies^[@bibr25-1756283X17750355]^ was excluded from the analysis, as it reported a very high rate of immunogenicity (79%) based on a small sample size (*n* = 28). The percentage of patients with ADAbs to IFX varied widely, from 0% to 65.3% ([Table 1](#table1-1756283X17750355){ref-type="table"} and [Figure 2(a)](#fig2-1756283X17750355){ref-type="fig"}).

![Rate of ADAbs formation to (a) IFX and (b) ADM.\
Note: circled data point indicates study excluded from analysis as it had a small sample size (*n* = 28) and a high rate of immunogenicity (79%).\
ADAbs, anti-drug antibodies; ADM, adalimumab; IFX, infliximab; LTE, long-term extension; *n*, number; RCT, randomized controlled trial.](10.1177_1756283X17750355-fig2){#fig2-1756283X17750355}

Rates of immunogenicity in patients receiving treatment with adalimumab {#section11-1756283X17750355}
-----------------------------------------------------------------------

A total of 25 publications were identified, representing 23 studies. As was the case with IFX, the majority of these (43.5%) were prospective observational studies. All but one of the studies reported the percentage of patients with CD or UC who developed ADAbs to ADM, which varied from 0.3% to 38% ([Table 1](#table1-1756283X17750355){ref-type="table"} and [Figure 2(b)](#fig2-1756283X17750355){ref-type="fig"}).

Rates of immunogenicity in patients receiving treatment with certolizumab pegol, golimumab, ustekinumab and vedolizumab {#section12-1756283X17750355}
-----------------------------------------------------------------------------------------------------------------------

CZP is approved for use in CD and not UC; therefore, in line with the approved indication, only studies reporting immunogenicity to CZP in CD were identified. These studies reported the percentage of patients developing ADAbs to CZP as ranging from 3.3% to 25.3% ([Table 1](#table1-1756283X17750355){ref-type="table"}). VDM is approved in both CD and UC, and identified studies reported immunogenicity developing in between 1% and 4.1% of patients ([Table 1](#table1-1756283X17750355){ref-type="table"}). GLM is not approved for use in CD. Two RCTs of GLM use in UC were identified, reporting that ADAbs were detected in 0.4% and 2.9% of patients ([Table 1](#table1-1756283X17750355){ref-type="table"}). In the single identified study of UST immunogenicity, 0.7% of patients in an RCT of UST in CD developed ADAbs ([Table 1](#table1-1756283X17750355){ref-type="table"}).

Impact of ADAb formation on treatment efficacy {#section13-1756283X17750355}
----------------------------------------------

In most of the included studies that evaluated efficacy, the presence of ADAbs was associated with a reduction in efficacy. Efficacy was assessed in a variety of ways, including Crohn's Disease Activity Index (CDAI) response/remission, Mayo response, endoscopic improvement and treatment discontinuation. In studies of IFX, the proportion of patients achieving and maintaining a response was generally lower for patients with detected ADAbs than those without detected ADAbs ( [Supplementary Table 7](http://journals.sagepub.com/doi/suppl/10.1177/1756283X17750355)). ADAbs to ADM were also associated with reduced efficacy and a loss of response, together with a high rate of secondary treatment failure; these associ-ations were shown to be statistically significant in some studies ( [Supplementary Table 8](http://journals.sagepub.com/doi/suppl/10.1177/1756283X17750355)). In one study,^[@bibr26-1756283X17750355]^ discontinuation of ADM treatment was reported to be very high (83.3%) in patients with ADAbs ( [Supplementary Table 8](http://journals.sagepub.com/doi/suppl/10.1177/1756283X17750355)).

Impact of ADAb formation on treatment safety {#section14-1756283X17750355}
--------------------------------------------

In studies of IFX, AEs were more common in patients with ADAbs than in those without ADAbs. AEs observed included a higher proportion reporting infusion-related reactions. The studies for ADM, CZP, GLM, VDM or UST reported either no safety data segmented by ADAbs status or no increased safety concerns associated with the development of ADAbs.

Impact of ADAb formation on treatment pharmacokinetics {#section15-1756283X17750355}
------------------------------------------------------

For studies included in this review in which serum levels of biologics were reported -- ADM, CZP and IFX -- ADAbs-positive patients had lower serum levels of the biologic than ADAbs-negative patients ([Table 2](#table2-1756283X17750355){ref-type="table"}).^[@bibr27-1756283X17750355][@bibr28-1756283X17750355][@bibr29-1756283X17750355][@bibr30-1756283X17750355][@bibr31-1756283X17750355][@bibr32-1756283X17750355][@bibr33-1756283X17750355][@bibr34-1756283X17750355][@bibr35-1756283X17750355][@bibr36-1756283X17750355][@bibr37-1756283X17750355][@bibr38-1756283X17750355][@bibr39-1756283X17750355][@bibr40-1756283X17750355][@bibr41-1756283X17750355][@bibr42-1756283X17750355][@bibr43-1756283X17750355][@bibr44-1756283X17750355][@bibr45-1756283X17750355][@bibr46-1756283X17750355][@bibr47-1756283X17750355]--[@bibr48-1756283X17750355]^

###### 

Serum levels of biologics in patients with and without ADAbs.

![](10.1177_1756283X17750355-table2)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                                                        Disease           Study design (number of patients assessed)   Biologic agent, sampling time and other specifications   Serum concentration of biologic agent (µg/mL)^[a](#table-fn5-1756283X17750355){ref-type="table-fn"}^   *p* value   
  -------------------------------------------------------------- ----------------- -------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ----------- ---------------
  Imaeda and colleagues^[@bibr35-1756283X17750355]^              CD                Prospective cohort study (58)                IFX: trough                                              0.2                                                                                                    3.4         *p* \< 0.01

  Levesque and colleagues^[@bibr36-1756283X17750355]^            CD                Prospective cohort study (327)               IFX: 0 weeks\                                            1.5\                                                                                                   6.4\        --\
                                                                                                                                IFX: 8 weeks                                             1.6                                                                                                    7.4         --

  Vermeire and colleagues^[@bibr37-1756283X17750355]^            CD                Prospective cohort study (174)               IFX: 4 weeks\                                            \                                                                                                      \           \
                                                                                                                                 ADAbs conc. \<8 µg/mL\                                  12.3\                                                                                                  10.1\       --\
                                                                                                                                 ADAbs conc. ⩾8 and \<20 µg/mL\                          7.2\                                                                                                   10.1\       --\
                                                                                                                                 ADAbs conc. ⩾20 µg/mL                                   6.1                                                                                                    10.1        --

  Stein and colleagues^[@bibr28-1756283X17750355]^ (CA)          CD                Prospective cohort study (69)                IFX: 26 weeks\                                           0.9\                                                                                                   7.6\        --\
                                                                                                                                IFX: 52 weeks                                            2.5                                                                                                    9.5         --

  Ainsworth and colleagues^[@bibr38-1756283X17750355]^           CD                Retrospective cohort study (33)              IFX: 8 weeks\                                            \                                                                                                      \           \
                                                                                                                                 Maintained responders\                                  2.9\                                                                                                   NR\         --\
                                                                                                                                 Secondary non-responders\                               0.0\                                                                                                   NR\         --\
                                                                                                                                 Primary non-responders                                  30.0                                                                                                   NR          --

  Hämäläinen and colleagues^[@bibr46-1756283X17750355]^          CD or UC cohort   Prospective cohort study (28)                IFX: trough\                                             \                                                                                                      \           \
                                                                                                                                 Non-responders\                                         \<0.1\                                                                                                 NR\         --\
                                                                                                                                 Responders                                              \>2.2                                                                                                  NR          --

  Pallagi-Kunstár and colleagues^[@bibr39-1756283X17750355]^     CD or UC cohort   Prospective cohort study (67)                IFX: trough                                              2.7                                                                                                    3.9         *p* = 0.015

  Paul and colleagues^[@bibr40-1756283X17750355]^                CD or UC cohort   Prospective cohort study (103)               IFX: trough\                                             \                                                                                                      \           \
                                                                                                                                 IFX monotherapy\                                        2.4\                                                                                                   NR\         --\
                                                                                                                                 IFX plus immunosuppressants                             2.1                                                                                                    NR          --

  Rivera and colleagues^[@bibr29-1756283X17750355]^ (CA)         CD or UC cohort   Prospective cohort study (69)                IFX: trough                                              1.8                                                                                                    9.0         *p* \< 0.001

  Ungar and colleagues^[@bibr41-1756283X17750355]^               CD or UC cohort   Prospective cohort study (125)               IFX: trough\                                             \                                                                                                      \           \
                                                                                                                                 Responders\                                             4.6\                                                                                                   --\         --\
                                                                                                                                 Non-responders                                          0.7                                                                                                    --          --

  Zitomersky and colleagues^[@bibr42-1756283X17750355]^          CD or UC cohort   Prospective cohort study (134)               IFX: trough                                              1.0                                                                                                    12.2        *p* \< 0.0001

  Vande Casteele and colleagues^[@bibr47-1756283X17750355]^      CD or UC cohort   Retrospective cohort study (90)              IFX: 6 weeks                                             5                                                                                                      27          *p* = 0.003

  Frederiksen and colleagues^[@bibr30-1756283X17750355]^ (CA)    CD or UC cohort   Retrospective cohort study (189)             IFX: trough                                              0.0                                                                                                    1.8         *p* = 0.002

  Bodini and colleagues^[@bibr31-1756283X17750355]^ (CA)         CD                Prospective cohort study (23)                ADM: trough                                              7.5                                                                                                    9.5         *p* = 0.002

  Imaeda and colleagues^[@bibr43-1756283X17750355]^              CD                Prospective cohort study (40)                ADM: trough                                              5.5                                                                                                    16.0        --

  Yarur and colleagues^[@bibr32-1756283X17750355]^ (CA)          CD or UC cohort   Prospective cohort study (66)                ADM: timing unknown                                      5.7                                                                                                    12.5        --

  Frederiksen and colleagues (CA)^[@bibr30-1756283X17750355]^\   CD or UC cohort   Retrospective cohort study (142)             ADM: trough                                              0                                                                                                      8.3         *p* \< 0.0001
  Frederiksen and colleagues^[@bibr48-1756283X17750355]^                                                                                                                                                                                                                                                    

  Schreiber and colleagues^[@bibr44-1756283X17750355]^\          CD                RCT (668)                                    CZP:\                                                    \                                                                                                      \           \
  Sandborn and colleagues^[@bibr27-1756283X17750355]^\                                                                           26 weeks\                                               6.1\                                                                                                   23.8\       --\
  Lichtenstein and colleagues^[@bibr45-1756283X17750355]^\                                                                       40 weeks\                                               1.0\                                                                                                   9.0\        --\
  Sandborn and colleagues^[@bibr33-1756283X17750355]^                                                                            56 weeks\                                               0.9\                                                                                                   8.7\        --\
                                                                                                                                 72 weeks\                                               1.5\                                                                                                   8.7\        --\
                                                                                                                                 80 weeks                                                1.6                                                                                                    9.4         --

  Stefan and colleagues^[@bibr34-1756283X17750355]^ (CA)         CD                RCT and LTE (594)                            CZP: trough                                              2--4                                                                                                   8--12       --
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All values presented to a maximum of one decimal place.

ADAbs, anti-drug antibodies; ADM, adalimumab; CA, conference abstract; CD, Crohn's disease; conc., concentration; CZP, certolizumab pegol; IFX, infliximab; LTE, long-term extension; NR, not reported; RCT, randomized controlled trial; UC, ulcerative colitis.

Time course of immunogenicity {#section16-1756283X17750355}
-----------------------------

Minimal information was available regarding the earliest time at which immunogenicity was detected. Furthermore, the timing of dosing and subsequent testing for ADAbs varied between studies. The majority of studies reported ADAbs testing in serum taken prior to the next infusion (trough). ADAbs can occur as early as 10--14 days post-dosing, and this finding has been reported in some studies. However, ADAbs can also take months to reach detectable levels ([Table 3](#table3-1756283X17750355){ref-type="table"}).^[@bibr26-1756283X17750355],[@bibr37-1756283X17750355],[@bibr38-1756283X17750355],[@bibr41-1756283X17750355],[@bibr47-1756283X17750355],[@bibr49-1756283X17750355][@bibr50-1756283X17750355][@bibr51-1756283X17750355][@bibr52-1756283X17750355][@bibr53-1756283X17750355][@bibr54-1756283X17750355][@bibr55-1756283X17750355][@bibr56-1756283X17750355][@bibr57-1756283X17750355][@bibr58-1756283X17750355][@bibr59-1756283X17750355][@bibr60-1756283X17750355]--[@bibr61-1756283X17750355]^

###### 

Time to detection of ADAbs.

![](10.1177_1756283X17750355-table3)

  ----------------------------------------------------------------------------------------------------------------------------------------------
  Author                                                           Disease     Number of patients   ADAbs first detected      Biologic therapy
  ---------------------------------------------------------------- ----------- -------------------- ------------------------- ------------------
  Baert and colleagues^[@bibr58-1756283X17750355]^\                CD          125                  After first infusion      IFX
  Magdelaine-Beuzelin and colleagues^[@bibr59-1756283X17750355]^                                                              

  Vermeire and colleagues^[@bibr37-1756283X17750355]^              CD          174                  After first infusion      IFX

  Schatz and colleagues^[@bibr52-1756283X17750355]^ (CA)           CD and UC   50                   Before second infusion    IFX

  Ungar and colleagues^[@bibr41-1756283X17750355]^                 CD and UC   125                  2 weeks                   IFX

  Steenholdt and colleagues^[@bibr60-1756283X17750355]^\           CD and UC   180                  Third infusion            IFX
  Steenholdt and colleagues^[@bibr51-1756283X17750355]^                                                                       

  Vande Casteele and colleagues^[@bibr47-1756283X17750355]^        CD and UC   90                   4 weeks/fourth infusion   IFX

  Vande Casteele and colleagues^[@bibr53-1756283X17750355]^ (CA)   CD and UC   57                   7 weeks                   IFX

  Ainsworth and colleagues^[@bibr38-1756283X17750355]^             CD          33                   8 weeks                   IFX

  Vande Casteele and colleagues^[@bibr54-1756283X17750355]^ (CA)   CD and UC   52                   8 weeks/third infusion    IFX

  Rosenthal and colleagues^[@bibr55-1756283X17750355]^ (CA)        CD and UC   38                   \<14 weeks                IFX

  Colombel and colleagues^[@bibr50-1756283X17750355]^              CD          219                  30 weeks                  IFX

  Hanauer and colleagues^[@bibr56-1756283X17750355]^               CD          299                  2 weeks                   ADM

  West and colleagues^[@bibr61-1756283X17750355]^                  CD          25                   10 weeks                  ADM

  Karmiris and colleagues^[@bibr26-1756283X17750355]^\             CD          148                  12 weeks                  ADM
  Baert and colleagues^[@bibr57-1756283X17750355]^                                                                            

  Sandborn and colleagues^[@bibr49-1756283X17750355]^              UC          721                  6 weeks                   GLM
  ----------------------------------------------------------------------------------------------------------------------------------------------

ADAbs, anti-drug antibodies; ADM, adalimumab; CA, conference abstract; CD, Crohn's disease; GLM, golimumab; IFX, infliximab; UC, ulcerative colitis.

Pharmacoeconomics {#section17-1756283X17750355}
-----------------

We identified only one study that addressed pharmacoeconomic issues related to the development of immunogenicity to biologic therapy in IBD; this Danish study involved 69 patients with CD with secondary IFX failure receiving either IFX dose intensification (5 mg/kg every 4 weeks) or interventions based on serum IFX and IFX antibody levels.^[@bibr62-1756283X17750355]^ The authors concluded that monitoring of ADAbs to IFX in patients with CD was more cost-effective than dose escalation without drug monitoring and immunogenicity assessment.

Discussion {#section18-1756283X17750355}
==========

Development of immunogenicity occurs with all six of the biologic agents investigated in patients with IBD. Huge variability in the rate of immunogenicity was observed, depending on the timing of sampling, the assay technique (drug sensitive *versus* drug tolerant), the study population (agent-naïve or experienced and concomitant medications taken), the setting (RCTs *versus* observational study), and the criteria for a positive finding (a single sample or multiple samples above the defined threshold). Care must therefore be taken in the interpretation and comparison of these findings.

The timing of sampling (prior to or just after the next administration) greatly influences the detection rate. Most assays do not detect ADAbs in the presence of drug; since drug concentration is the lowest just before the next infusion, this is the optimal time to sample. This might be one explanation for the formation of ADAbs being reported to be lower in RCTs than in observational studies. Often, a limited number of time points were studied, and insufficient time was allowed for drug levels to decrease prior to sampling. However, it is also likely that improved assay techniques used in observational studies, together with the selection of patients with loss of response, led to higher levels of detection of ADAbs than in RCTs.

The immunogenicity reported for biologic agents used in IBD may adversely impact pharmacokinetics, efficacy and safety. Development of ADAbs to biologic therapy may therefore have a substantial impact on patients with IBD, as the consequent loss of efficacy and the increased potential for AEs is likely to result in a worsening of their condition, and a switch in their treatment may be required.^[@bibr6-1756283X17750355]^ Despite the range of treatments available for both CD and UC, the development of ADAbs to biologics, and the resultant impact, means that there is still an unmet treatment need in these diseases. Both European and US treatment guidelines require investigation of the immunogenic potential of biologic therapies when seeking marketing authorization for a new product for all indications, including CD and UC, and post-marketing monitoring of the development of immunogenicity.^[@bibr63-1756283X17750355],[@bibr64-1756283X17750355]^

ADAbs produced in response to TNF inhibitors (TNFi) may be neutralizing or non-neutralizing, depending on the binding site. Neutralizing ADAbs produced in response to TNFi bind to the epitope binding (Fab′)~2~ region of the TNFi, thereby reducing the agents' therapeutic activity.^[@bibr65-1756283X17750355]^ By contrast, non-neutralizing antibodies do not prevent binding of the agents to target molecules, and hence do not reduce the efficacy of biologic agents; they do, however, impact the pharmacokinetics, by accelerating clearance of the agent.^[@bibr66-1756283X17750355]^ It is also known that some ADAbs are transient in nature. These may appear at any time during treatment and seem to be of little clinical significance compared to persistent ADAbs.^[@bibr47-1756283X17750355],[@bibr53-1756283X17750355],[@bibr54-1756283X17750355]^

Giving biologic therapies in combination with concomitant immunosuppressive agents has been shown in several studies to reduce the development of ADAbs.^[@bibr67-1756283X17750355],[@bibr68-1756283X17750355]^ One meta-analysis demonstrated that the use of concomitant immunosuppressants, primarily MTX, reduced the proportion of patients on IFX and ADM with detectable ADAbs by about 41% in those with rheumatoid arthritis, spondyloarthritis, psoriasis and IBD.^[@bibr67-1756283X17750355]^ However, the mechanism for this attenuation is not fully understood.^[@bibr68-1756283X17750355]^ Therefore, reducing the likelihood of a patient developing an immunogenic response to a biologic therapy may influence decisions made by the clinician in regard to the treatment prescribed for patients with IBD. There is evidence that scheduled treatment with IFX not only results in improved efficacy^[@bibr69-1756283X17750355]^ compared with episodic treatment, but that this is associated with a reduced level of immunogenicity.^[@bibr70-1756283X17750355]^ Clinicians should also consider administering a loading dose of a biologic at the commencement of therapy, because, in addition to achieving therapeutic levels rapidly, this has been reported to reduce immunogenicity,^[@bibr71-1756283X17750355]^ as has intravenous hydrocortisone treatment immediately prior to infusion with IFX.^[@bibr72-1756283X17750355]^

Potential limitations of the present study include the diversity of study design, patient populations, disease severity, concomitant therapies, assay methods and timing of the studies reviewed. This lack of standardization limited comparison across studies and between therapies. In addition, limited information was available for a number of the biologic agents included in the systematic literature search, with over 90% of studies reporting on IFX and ADM, reflecting the time these agents have been on the market compared to the other agents investigated. Not all studies reported data for some of the immunogenicity-related outcomes related to efficacy and safety, limiting conclusions on the impact of the development of ADAbs. It is also possible that rates of immunogenicity, as well as safety and efficacy outcomes, may have been underestimated in a number of the studies included in the review, due to insufficient sensitivity of the assay techniques used, small sample sizes, and limited follow-up of sampling (after wash-out of the biologic agent).

The potential clinical implication of lower biologic serum concentrations, reduced efficacy, and increased safety issues in the presence of immunogenicity is a concern for effective treatment and requires further study. In particular, more studies are required to assess the immunogenic potential of the more recently approved biologics. However, this analysis suggests that agents that elicit the lowest rate of immunogenicity may be preferential for treating CD and UC. Immunogenicity is one of the major causes for loss of response to biologic therapy,^[@bibr13-1756283X17750355]^ but immunogenicity must be assessed and interpreted in an appropriate manner. It is essential that research to improve understanding of immunogenicity and identify agents with limited immunogenic potential continues, in order to provide safe and effective treatment options.
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